This site is intended for health professionals only!

Published on 7 July 2009

Share this story:

Shire files alternative treatment for Gaucher Disease


Global speciality Biopharmaceutical company Shire has filed a treatment protocol for velaglucerase alfa in development for the treatment of Gaucher disease. Due to a potential restriction on the approved treatment of the disease the new treatment was developed at the request of the FDA.

Velaglucerase alfa is made with Shire’s proprietary technology, in a human cell line. The enzyme produced has the exact human amino acid sequence and carries a human glycosylation pattern.

If approved by the FDA, Shire would provide the treatment free of charge allowing physicians to treat patients with Gaucher disease and have a sufficient supply of velaglucerase alfa to meet patient demand. The company is now working with the FDA to file a New Drug Application (NDA) for velaglucerase alfa as early as possible in order to treat the genetic disease.


Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine